· SNAC is the lead participant in a successful CRC-P grant application: AI: new smarts for the medical imaging industry
· The CRC-P grant provides A$2.36 million funding, with additional matched cash and in-kind participant funding.
· Together with national imaging provider I-MED Radiology Network (I-MED) and the University of Sydney’s Brain and Mind Centre, SNAC will develop, implement and commercialise clinically meaningful AI algorithms in the clinical and clinical trials neuroimaging space.
Sydney Neuroimaging Analysis Centre (SNAC) is pleased to announce its recent success in securing support for its Artificial Intelligence in Neuroimaging project through the Australian Government’s Cooperative Research Centres (CRC) Programme. As the lead participant, SNAC has been awarded a A$2.36 million grant, with matched cash and in-kind funding from the project participants, including SNAC, I-MED and the University of Sydney’s Brain and Mind Centre.
The Cooperative Research Centres (CRC) Programme is administered by AusIndustry, a division within the Department of Industry, Innovation and Science. The CRC Programme is a competitive, merit based grant programme that supports industry-led and outcome-focused collaborative research partnerships between industry, researchers and the community.
Dr Tim Wang PhD, Director of Operations for SNAC, said “The provision of CRC-P funding will significantly accelerate the expansion of SNAC’s neuro-imaging biomarker portfolio, enhance clinical trials of emerging therapies for neurological disorders such as multiple sclerosis and, through our partnership with I-MED, transform diagnostic neuroimaging”
“Partnership with the Computational Neuroscience Team at the University of Sydney’s Brain and Mind Centre, led by neurologist Professor Michael Barnett and AI expert Professor Dacheng Tao, is a pivotal strength of the project”.
SNAC specialises in the provision of regulatory-compliant neuroimaging analysis to the pharmaceutical industry and in particular the development of novel neuroimaging biomarkers and their implementation in Phase 2-4 clinical trials. SNAC also works closely with academics in imaging science and clinical medicine to further research into neurological disease.
For more information please contact:
Dr Tim Wang, Director of Operations